Kantarjian H - Search Results

1

The role of decitabine in the treatment of myelodysplastic syndromes.

Atallah E, Kantarjian H, Garcia-Manero G. Atallah E, et al. Among authors: kantarjian h. Expert Opin Pharmacother. 2007 Jan;8(1):65-73. doi: 10.1517/14656566.8.1.65. Expert Opin Pharmacother. 2007. PMID: 17163808 Review.

2

AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.

Estey E, Trujillo JM, Cork A, O'Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S. Estey E, et al. Among authors: kantarjian h. Hematol Pathol. 1992;6(1):43-8. Hematol Pathol. 1992. PMID: 1601822

3

Treatment of myelodysplastic syndromes with AML-type chemotherapy.

Estey E, Pierce S, Kantarjian H, O'Brien S, Beran M, Andreeff M, Escudier S, Koller C, Kornblau S, Robertson L, et al. Estey E, et al. Among authors: kantarjian h. Leuk Lymphoma. 1993;11 Suppl 2:59-63. doi: 10.3109/10428199309064263. Leuk Lymphoma. 1993. PMID: 7510196 Clinical Trial. No abstract available.

4

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, et al. Estey E, et al. Among authors: kantarjian h. J Clin Oncol. 1994 Apr;12(4):671-8. doi: 10.1200/JCO.1994.12.4.671. J Clin Oncol. 1994. PMID: 7512125 Clinical Trial.

5

The expanding role of fludarabine in hematologic malignancies.

Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Li YY, Gandhi V, et al. Keating MJ, et al. Among authors: kantarjian h. Leuk Lymphoma. 1994;14 Suppl 2:11-6. doi: 10.3109/10428199409052690. Leuk Lymphoma. 1994. PMID: 7533576 Review.

6

Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.

Robertson LE, Estey E, Kantarjian H, Koller C, O'Brien S, Brown B, Keating MJ. Robertson LE, et al. Among authors: kantarjian h. Leukemia. 1994 Dec;8(12):2047-51. Leukemia. 1994. PMID: 7807993

7

Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes.

Cortes J, O'Brien S, Kantarjian H, Cork A, Stass S, Freireich EJ, Keating M, Pierce S, Estey E. Cortes J, et al. Among authors: kantarjian h. Leukemia. 1994 Dec;8(12):2174-8. Leukemia. 1994. PMID: 7808007

8

Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes.

Cortes JE, Kantarjian H, O'Brien S, Keating M, Pierce S, Freireich EJ, Estey E. Cortes JE, et al. Among authors: kantarjian h. Leukemia. 1995 Jan;9(1):115-7. Leukemia. 1995. PMID: 7845005

9

Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.

Estey EH, Kantarjian H, Keating M. Estey EH, et al. Among authors: kantarjian h. Semin Oncol. 1993 Dec;20(6 Suppl 8):1-5. Semin Oncol. 1993. PMID: 8290966 Clinical Trial.

10

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.

Beran M, Kantarjian H, O'Brien S, Koller C, al-Bitar M, Arbuck S, Pierce S, Moore M, Abbruzzese JL, Andreeff M, Keating M, Estey E. Beran M, et al. Among authors: kantarjian h. Blood. 1996 Oct 1;88(7):2473-9. Blood. 1996. PMID: 8839838 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,546 results

Search Page

Filters